EHA-SWG Scientific Meeting on Acquired Aplastic Anemia
Dates: April 29 – May 1, 2021
Chair: C Dufour
Organized in collaboration with: EHA & the EHA Scientific Working Group on Granulocyte and Constitutional Marrow Failure Syndromes.
SAVE THE DATE!
This scientific meeting on Acquired Aplastic Anemia, presents a worldwide approach to the topic and offers an excellent opportunity for participants to learn about each aspect of the disease in one go. The meeting will be delivered in a virtual format with on-demand content and live sessions on April 29 to May 1.
Registration and abstract submission will open soon.
Junior and senior hematologist with an interest in Acquired Aplastic Anemia.
This meeting will cover the following topics:
- Epidemiology and pathophysiology
- Diagnosis and treatment of severe aplastic anemia (SAA) in Europe and beyond
- Treatment of paroxysmal nocturnal hemoglobinuria (PNH)
- Treatment of moderate aplastic anemia
- Supportive treatment options
- Special aspects of acquired aplastic anemias
- Stakeholder perspectives
- Future outlooks
The complete program will be published soon.
Abstract & case submission
Abstract and case submission is an important part of EHA-SWG Scientific Meeting programs. As a participant, you have the opportunity to submit an abstract or clinical case for this meeting, and (if accepted) discuss it with the international faculty and peers.
A selection of abstracts and clinical cases will be eligible for acceptance during the meeting, the presentation format will be in the form of oral presentations or poster presentations. Presenting authors will receive a separate invitation.
More information on the abstract and case submission will be available soon.
After attending this EHA-SWG Scientific Meeting, delegates will be able to:
- recognize acquired aplastic anemia (AAA) and PNH,
- differentiate AAA and PNH from myelodysplastic syndromes (MDS) and constitutional marrow failures,
- understand the best currently available treatment options tailored on patients age, comorbidities and geographic area,
- understand the newly developed "intelligent" drugs for AA and PNH,
- understand the new pathogenetic determinant of AAA and PNH, and
- understand the clinical relevance of the molecular markers of clonal evolution to MDS/AML.
EBAH CME Accreditation
Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting will be accredited by the EBAH system. Participants of this meeting are eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.